Sun Pharmaceutical Industries Ltd.

Sun Pharma is currently trading at Rs. 1118.20, up by 24.35 points or 2.23% from its previous closing of Rs. 1093.85 on the BSE.

The scrip opened at Rs. 1100.05 and has touched a high and low of Rs. 1124.45 and Rs. 1100.00 respectively. So far 51,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1132.70 on 18-Jul-2013 and a 52 week low of Rs. 614.55 on 26-Jul-2012.

Last one week high and low of the scrip stood at Rs. 1130.90 and Rs. 1068.75 respectively. The current market cap of the company is Rs. 1, 15,795 crore.

The promoters holding in the company stood at 63.68% while Institutions and Non-Institutions held 26.00% and 10.32% respectively. Sun Pharmaceutical Industries’ subsidiary has been granted a final approval from USFDA for its Abbreviated New Drug Applications (ANDA) for generic version of Prandin, Repaglinide tablets. Sun Pharma’s subsidiary, being the first-to-file an ANDA for generic Prandin with a Para IV certification, is eligible for a 180-day marketing exclusivity in the US.

Repaglinide tablets, 1 mg and 2 mg are therapeutic equivalents of Novo Nordisk’s Prandin tablets. These tablets have annual sales of approximately $200 million in the US. Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus.

Sun Pharmaceutical Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.